
|Articles|October 15, 2014
- Gastrointestinal Cancers (Issue 3)
- Volume 3
- Issue 1
Immunotherapy and Viral Therapy for Pancreatic Cancer
Tanios Bekaii-Saab, MD, discusses the future of immunotherapy and viral therapy for the treatment of pancreatic cancer.
Advertisement
Articles in this issue
over 11 years ago
Unanswered Questions Regarding the Treatment of Pancreatic NETsover 11 years ago
Targeted Agents and Combinations Being Studied in Pancreatic NETsover 11 years ago
Sequencing Agents for the Treatment of Pancreatic NETsover 11 years ago
Research on Epidemiology of GIST Identifies Risk Factorsover 11 years ago
Antiangiogenic Strategies for mCRC Need Further Explorationover 11 years ago
Coping With Comorbidities in Hepatocellular Cancerover 11 years ago
Strategies in Surveillance: Hepatocellular CarcinomaAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
4
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
5
































